|
Patent landscape, scope, and claims: |
US Patent 9,138,404: Scope, Claim-by-Claim Boundaries, and Landscape Impact for IV Ibuprofen in Critically Ill Pain Patients
What does US 9,138,404 claim protect?
US Patent 9,138,404 claims methods of treating pain in critically ill patients using intravenous (IV) ibuprofen with specific dose and pharmacokinetic targets and a critically ill/non-critically ill pharmacokinetic non-equivalence requirement. The claims are drafted to narrow infringement to a particular PK window (Cmax and/or AUC) tied to dosing about 400 mg to about 800 mg every about 4 to about 6 hours, in a defined critically ill context (ICU and/or device support and/or concomitant therapies), and explicitly distinguishes the regimen from an equivalent regimen administered to non-critically ill patients.
Core protection is not a general pain-treatment indication for IV ibuprofen. It is a method claim requiring all (or nearly all) of the following elements, depending on claim version:
- Patient population: critically ill and not being treated for inflammation
- Route and drug: IV ibuprofen
- Dosage regimen: ~400 mg to ~800 mg administered every ~4 to ~6 hours
- PK metrics: Cmax and/or mean AUC ranges or target equivalents
- PK non-equivalence: the critically ill patient PK profile is not equivalent to the PK profile produced by administering the same IV dosing regimen to non-critically ill patients
- Additional contextual constraints: critically ill features such as vasopressors, mechanical ventilation, pulmonary artery catheter, arterial blood pressure catheter, ICU care, packed red blood cells, multiple antibiotics
How is “critically ill” operationalized in the claims?
The claims do not define “critically ill” by diagnosis codes. They define it by treatment setting and co-therapies/device supports, including at least one of:
- vasopressor support treatment
- mechanical ventilation treatment
- pulmonary artery catheter treatment
- arterial blood pressure catheter treatment
- Intensive Care Unit treatment
- packed red blood cells administration
- multiple antibiotics administration
The language ties the protected method to patients with ICU-level support, and then uses that status to justify the PK non-equivalence requirement and the PK ranges.
What does claim 1 require (the independent claim)?
Claim 1 is the anchor. It requires:
- Method of treating pain in critically ill patients in need thereof
- Administer an IV ibuprofen pharmaceutical composition
- Dosage regimen: about 400 mg to about 800 mg every 4 to 6 hours
- A pharmacokinetic outcome in critically ill patients of at least one type:
- (i) Cmax ~20.8 to ~75 μg/mL, or
- (ii) mean AUC ~36.8 to ~117.5 μg·h/mL, or
- (iii) both (i) and (ii)
- Non-equivalence limitation: the regimen produces a PK profile in critically ill patients that is not equivalent to the PK profile produced by the same dosing regimen in non-critically ill patients
- Non-inflammation condition: critically ill patients are not being treated for inflammation
- Critical illness receiving at least one enumerated ICU support/therapy:
- vasopressors, mechanical ventilation, pulmonary artery catheter, arterial blood pressure catheter, ICU treatment, packed red blood cells, multiple antibiotics
- Pain is thereby treated
Practical scope interpretation
Claim 1 is written to be infringement-proof against a straightforward “IV ibuprofen in ICU pain” argument unless the accused regimen:
- hits the specific dose interval (400–800 mg; 4–6 hour cadence), and
- meets a defined PK window, and
- can be framed as PK non-equivalent versus the non-critically ill population receiving the same dosing regimen.
What are claims 2–10 narrowing within claim 1’s framework?
These are dependent on claim 1’s independent framework and carve by dose and corresponding PK.
Dose-specific embodiments
- Claim 2: dosing comprises about 800 mg
- Claim 4: dosing comprises about 400 mg
- Claim 9: dose selected from 400, 450, 500, 550, 600, 650, 700, 800 mg
- Claim 10: dose selected from 400 mg and 800 mg only
PK windows tied to those doses
For the 800 mg embodiment:
- Claim 3: mean Cmax within ~80% to ~125% of 60 μg/mL
- Claim 6: mean (AUC)0-t within ~80% to ~125% of 94 μg·h/mL
For the 400 mg embodiment:
- Claim 5: mean Cmax within ~80% to ~125% of 25.7 μg/mL
- Claim 7: mean (AUC)0-t within ~80% to ~125% of 45.9 μg·h/mL
Dosing interval limitations
- Claim 8: critically ill dosing interval is shorter than any dosing interval used in the non-critically ill regimen
How the dependent claims tighten infringement
The dependent claims are designed so that a competitor can’t easily avoid infringement by:
- using the same dose amount but missing the PK window, or
- using a different schedule but still arguing equivalence (because claim 8 imposes “shorter interval” versus non-critically ill schedules).
How do claims 11–20 differ from claim 1?
Claim 11 is another independent-style claim (not explicitly dependent on claim 1). It is broader in structure but similarly narrow in constraints:
- IV ibuprofen regimen in critically ill pain patients
- dose ~800 mg
- PK targets specified as mean windows:
- Cmax 80–125% of ~60 μg/mL
- AUC 80–125% of ~94 μg·h/mL
- critically ill not suffering from inflammation and receiving at least one listed ICU therapy/support
This claim locks both Cmax and AUC simultaneously to the 800 mg regimen.
Dependent refinements of claim 11
- Claim 12: (AUC)0-t within 80–125% of 94 μg·h/mL
- Claim 13: dosing interval selected from about 4 hours and about 6 hours
- Claim 14: dosing interval is every 4 to 6 hours
- Claim 15: critically ill in ICU
- Claim 16: receiving packed red blood cells
- Claim 17: receiving vasopressor support
- Claim 18: receiving multiple antibiotics
- Claim 19: receiving mechanical ventilation
- Claim 20: receiving pulmonary catheter or arterial blood pressure catheter
What is the protected “PK non-equivalence” hook, and why it matters?
Claim 1’s most litigable feature is the requirement that:
- critically ill PK is not equivalent to non-critically ill PK when the same dosing regimen is administered.
This is a comparative limitation. It pushes enforceability beyond:
- “dose amount and schedule” alone, and into
- comparative PK profiling evidence between populations.
For a validity or infringement defense, parties typically dispute one of:
- the meaning of “equivalent” in PK terms (implicit equivalence threshold is not spelled out in the claim text you provided),
- whether the accused regimen’s PK actually falls into the claimed Cmax/AUC ranges, and
- whether the patient population fits the claim-defined “not treated for inflammation” and critical illness conditions.
Where are the practical boundary lines for competitors?
Dosing and schedule boundaries
The claimed regimen class centers on:
- about 400–800 mg
- every about 4–6 hours
And in narrower dependent claims:
- every 4 hours or every 6 hours (claim 13)
- critically ill interval shorter than non-critically ill interval (claim 8)
A competitor that uses:
- a dose outside 400–800 mg, or
- a cadence outside 4–6 hours,
creates a direct pathway to non-infringement for claims that require those regimen constraints.
PK target boundaries
The claims include two types of PK constraints:
- Absolute windows (claim 1):
- Cmax 20.8 to 75 μg/mL
- mean AUC 36.8 to 117.5 μg·h/mL
- Relative windows using an “80% to 125% of target” approach (claims 3, 5, 6, 7, 11, 12):
- Example (800 mg):
- Cmax in 80–125% of 60
- AUC in 80–125% of 94
This structure is engineered so that a competitor cannot avoid the claim by minor numeric drift unless that drift moves the results outside the constructed windows.
Patient status boundaries
A product label or clinical protocol must grapple with:
- “critically ill” as defined by ICU supports/therapies,
- “not being treated for inflammation,” and
- the presence of at least one enumerated ICU feature.
This is a meaningful boundary for trials or real-world use where patients receive anti-inflammatory care for other indications.
Claim design summary (scope map)
What is covered most tightly?
- IV ibuprofen at 800 mg every 4–6 hours (or specifically 4 or 6 hours) for pain in critically ill patients with enumerated ICU supports and no inflammation treatment, achieving:
- mean Cmax in 80–125% of 60 μg/mL
- mean AUC in 80–125% of 94 μg·h/mL
(Claims 11, 3, 6, 12, 13, 14, plus the ICU support-specific dependent claims.)
What is covered more broadly?
- Claim 1 covers:
- 400–800 mg every 4–6 hours
- with either Cmax or AUC in absolute windows
- plus the PK non-equivalence constraint
That makes claim 1 the more general enforcement vehicle if PK evidence can support “not equivalent” to non-critically ill PK.
How does this interact with the US patent landscape (what matters for filings)?
For business and patent strategy, the key landscape question is whether there are:
- other US patents on IV ibuprofen formulations (composition/pH/solubilization),
- other patents on ibuprofen dosing in ICU/critically ill populations,
- other patents on analgesia in ICU, even if using different NSAIDs,
- patents on PK modeling and patient subgrouping, and
- whether 9,138,404 is part of a family with continuation claims that extend claim coverage.
However, no patent-family, prosecution history, or citation graph data was provided in your prompt. Without those data, a complete landscape mapping cannot be produced from the claim text alone.
Freedom-to-operate (FTO) implications of the claim set you provided
The claim set is method-based and requires a factual record:
- treatment in a defined critically ill population,
- drug administration at specified dose/schedule,
- PK outcomes matching claimed windows, and
- comparative PK “not equivalent” for claim 1.
That combination tends to shift FTO risk to:
- protocols that generate PK comparable to the patent’s targets, and
- clinical programs where PK is measured and would be used in regulatory and payer dossiers.
From a litigation perspective, enforcement typically relies on clinical/PK study data, lab sampling, and dose administration records.
Key numeric constraints embedded in the claims
Claim 1 (broadest independent)
- Dose: ~400–~800 mg
- Interval: every ~4–~6 hours
- Critically ill pain treatment; not inflammation; has at least one ICU support/therapy
- PK:
- Cmax ~20.8–~75 μg/mL, or
- mean AUC ~36.8–~117.5 μg·h/mL, or
- both
- plus PK non-equivalence vs non-critically ill receiving same dosing regimen
Claim 11 (800 mg tight)
- Dose: ~800 mg
- Mean PK targets:
- Cmax within 80–125% of ~60 μg/mL
- AUC within 80–125% of ~94 μg·h/mL
- Critically ill; not inflammation; at least one ICU support/therapy
Dependent dose-specific PK windows
- 800 mg:
- mean Cmax: 80–125% of 60 μg/mL
- mean AUC0-t: 80–125% of 94 μg·h/mL
- 400 mg:
- mean Cmax: 80–125% of 25.7 μg/mL
- mean AUC0-t: 80–125% of 45.9 μg·h/mL
Key Takeaways
- US 9,138,404 protects a specific IV ibuprofen dosing-and-PK method for pain in critically ill patients, under conditions of no inflammation treatment and presence of enumerated ICU supports/therapies.
- Claim 1 is the core enforcement vehicle: it requires 400–800 mg every 4–6 hours, a PK window, and a critically ill vs non-critically ill PK non-equivalence limitation.
- Claims 11–14 tighten the protection around 800 mg with both Cmax and AUC mean targets and specified dosing intervals.
- The dependent claims add precision via:
- discrete dose amounts (400 mg and 800 mg),
- discrete interval options (4 or 6 hours),
- and ICU-subgroup presence (ventilation, vasopressors, catheters, packed RBCs, multiple antibiotics, ICU stay).
FAQs
-
Does the patent cover IV ibuprofen for pain in any patient population?
No. The claims require critically ill patients defined by ICU support/therapies and pain treatment, with an explicit not treated for inflammation condition.
-
Is the protected method limited to a single ibuprofen dose?
No. It spans about 400 mg to about 800 mg (claim 1), with additional dependent claims specifically targeting 400 mg and 800 mg, including an 800 mg independent-style claim (claim 11).
-
Must both Cmax and AUC be met for all claims?
No. Claim 1 allows meeting either Cmax or mean AUC (or both). Claim 11 requires both via its mean target structure.
-
What is the most distinctive claim limitation besides dosing?
The comparative requirement in claim 1: the critically ill patient PK profile must be not equivalent to the PK profile in non-critically ill patients receiving the same dosing regimen.
-
What kind of evidence typically matters for enforcement?
Evidence tying together: dose administration records, sampling for Cmax/AUC, confirmation that patients were critically ill under the claim’s enumerated support/therapy conditions, and documentation that patients were not being treated for inflammation.
References
[1] US Patent 9,138,404 (claims as provided in prompt).
More… ↓
⤷ Start Trial
|
